Literature DB >> 17329304

Is there a case for MDMA-assisted psychotherapy in the UK?

Ben Sessa1.   

Abstract

Much has been written in scientific and popular literature in recent years about the dangers surrounding the recreational use of the drug MDMA/ecstasy. What is little known and understood however is the history of the apparently safe and effective use of MDMA as a therapeutic tool for psychotherapy. In this paper the author explores this history and describes the recent re-emergence of scientific interest in MDMA and other psychedelic drugs. There are currently several new double-blind randomised controlled trials underway re-visiting the subject. By acknowledging the limitations of this new research and emphasising the importance of exercising appropriate but realistic caution, the author asks that the medical profession consider a dispassionate and open-minded debate to examine whether MDMA might have a legitimate place as an adjunct to psychotherapy in modern psychiatric practice.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17329304     DOI: 10.1177/0269881107069029

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  10 in total

Review 1.  Neuropsychiatric effects of prescription drug abuse.

Authors:  Jason P Caplan; Lucy A Epstein; Davin K Quinn; Jonathan R Stevens; Theodore A Stern
Journal:  Neuropsychol Rev       Date:  2007-08-16       Impact factor: 7.444

2.  Comment on the letter by Green, Gabrielsson, Marsden, and Fone, MDMA: on the translation from rodent to human dosing.

Authors:  Rafael de la Torre; Elena Puerta; Norberto Aguirre
Journal:  Psychopharmacology (Berl)       Date:  2009-01-16       Impact factor: 4.530

Review 3.  Neuropsychotherapy: conceptual, empirical and neuroethical issues.

Authors:  Henrik Walter; Mathias Berger; Knut Schnell
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-11       Impact factor: 5.270

4.  An Ethical Exploration of Barriers to Research on Controlled Drugs.

Authors:  Michael H Andreae; Evelyn Rhodes; Tyler Bourgoise; George M Carter; Robert S White; Debbie Indyk; Henry Sacks; Rosamond Rhodes
Journal:  Am J Bioeth       Date:  2016       Impact factor: 11.229

5.  The role of MDMA (Ecstasy) in coping with negative life situations among urban young adults.

Authors:  Lwendo S Moonzwe; Jean J Schensul; Kristin M Kostick
Journal:  J Psychoactive Drugs       Date:  2011 Jul-Sep

Review 6.  Lost in translation: preclinical studies on 3,4-methylenedioxymethamphetamine provide information on mechanisms of action, but do not allow accurate prediction of adverse events in humans.

Authors:  A R Green; M V King; S E Shortall; K C F Fone
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

Review 7.  Targeting memory processes with drugs to prevent or cure PTSD.

Authors:  Christopher K Cain; George D Maynard; John H Kehne
Journal:  Expert Opin Investig Drugs       Date:  2012-07-27       Impact factor: 6.206

8.  MDMA (3,4-Methylenedioxymethamphetamine) Analogues as Tools to Characterize MDMA-Like Effects: An Approach to Understand Entactogen Pharmacology.

Authors:  P Sáez-Briones; A Hernández
Journal:  Curr Neuropharmacol       Date:  2013-09       Impact factor: 7.363

9.  Harms and benefits associated with psychoactive drugs: findings of an international survey of active drug users.

Authors:  Celia J A Morgan; Louise A Noronha; Mark Muetzelfeldt; Amanda Feilding; Amanda Fielding; H Valerie Curran
Journal:  J Psychopharmacol       Date:  2013-02-25       Impact factor: 4.153

Review 10.  Pharmacological enhancement of exposure-based treatment in PTSD: a qualitative review.

Authors:  Rianne A de Kleine; Barbara O Rothbaum; Agnes van Minnen
Journal:  Eur J Psychotraumatol       Date:  2013-10-17
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.